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We prospectively evaluated the association between self-reported dietary intake and 
urinary metabolomic markers of habitual nut exposure with cognitive decline over a 3-
year follow-up in an older Italian population. 
Methods and results 
We selected 119 older participants, from the InCHIANTI cohort based on self referred 
nut intake: the non-nut consumer (n=72) and the regular nut consumer (≥2.9 g/d, n=47) 
groups. Nut exposure was measured at baseline either with the use of a validated food 
frequency questionnaire or with an HPLC-Q-ToF-MS metabolomic approach. Three 
years after, 28 from non-consumers group and 10 from consumers group experienced 
cognitive decline. Dietary nut exposure was characterized by urinary metabolites of 
polyphenols and fatty acids pathways. Nut consumption estimated either by the dietary 
marker or by the urinary marker model was in both cases associated with less cognitive 
decline (OR: 0.78, 95% CI: 0.61,0.99; P = 0.043 and OR: 0.995, 95% CI: 0.991,0.999; 
P = 0.016, respectively) with AUCs 73.2 (95% CI: 62.9,83.6) and 73.1 (62.5,83.7), 
respectively.  
Conclusions 
A high intake of nuts may protect older adults from cognitive decline. The use of a 
panel of metabolites provides accurate and complementary information of the nut 







A decline in cognitive function is a core feature of dementia, which represents a 
growing health problem worldwide [1]. The World Health Organization has predicted 
that the total number of people with dementia will rise up to 115.4 million by 2050 [2]. 
Accordingly, identifying effective strategies for preventing dementia or slowing down 
its progression is becoming a major public health priority. Accumulating evidence 
suggests an association between healthy cognitive function and dietary factors, in 
particular high vegetable and fruit intake, low saturated and trans fat intake, high long-
chain omega-3 fatty acid intake, and intake of vitamins E and B12 [3, 4]. Recent studies 
suggested that dietary intake of nuts is protective against cognitive decline [5]. Nuts 
contain large amounts of plant protein and unsaturated fatty acids, dietary fibre, 
vitamins (e.g., folic acid, niacin, tocopherols, vitamin B6), minerals (e.g., calcium, 
magnesium, potassium, zinc), and bioactive compounds such as phytosterols and 
phenolic compounds [6]. Its peculiar chemical composition is critical for providing their 
beneficial health effects. Indeed, epidemiological and clinical studies have associated 
exposure to nuts with a reduced risk of cardiovascular diseases, type 2 diabetes, cancer, 
metabolic syndrome and total mortality [7, 8]. Because of these data, nut intake is 
recommended in several dietary guidelines worldwide [9]. However, evidence that nut 
consumption is protective against cognitive decline is still scant [10].  
In addition, a general problem of the studies that evaluated the protective role of nut 
dietary consumption on cognitive decline is that nut exposure was only based on the 
assessment of dietary questionnaires, which lack precision and tend to be biased [11]. In 
order to better evaluate the association between dietary exposure and health outcomes, 
an accurate and objective assessment of the exposure is needed. The use of food 





approaches are progressively more used in nutritional studies, alone or in combination 
to self-reported dietary questionnaires [11].  
The aim of this study is to investigate the association between dietary and urinary 
markers of habitual nut exposure with cognitive decline over a 3-year follow-up in a 
cohort of Italian participants aged 65 years and older in the InCHIANTI (Invecchiare in 
Chianti (Aging in Chianti)) study. For this propose, we measured the nut exposure 
either by dietary questionnaire or by applying an untargeted metabolomic approach. We 
characterized the food metabolome associated with nut intake, and developed a potential 
model of urinary biomarkers for assessing habitual nut exposure accurately in the 
InCHIANTI cohort.  
 
2. Experimental Section 
STUDY POPULATION 
The InCHIANTI study is a population-based prospective cohort study located in two 
municipalities adjacent to the city of Florence (Italy), and it is described in detail 
elsewhere [12]. The study randomly sampled 1260 participants aged ≥ 65 years, of 
whom 1155 agreed to be enrolled. The participation rate was 91.7%. Of these, 82 
participants (7.1%) with dementia at baseline, according to criteria set out in the 
Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), were excluded. 
A total of 609 dementia-free participants aged ≥ 65 years were selected based on the 
availability of baseline 24 h urine samples (collected in 1998–2000), as well as baseline 
and 3-year follow-up cognitive assessment (administered in 1998–2000 and 2001–2003, 
respectively) (Supporting Information Figure 1). Finally, 119 subjects were selected 
based on baseline nut intake (see dietary assessment section for details) and randomly 





National Institute of Research and Care of Aging Ethical Committee approved the study 
protocol, and all participants provided informed consent to participate. 
DIETARY ASSESSMENT 
Nut intake was assessed at baseline with the use of the Italian version of the food 
frequency questionnaire (FFQ) developed and validated in the European Prospective 
Study into Cancer and Nutrition (EPIC) [14]. This questionnaire includes one item 
regarding the consumption of walnuts, almonds, hazelnuts and peanuts with four 
categories for the frequency of consumption (never, rarely, times per week or per 
month). In the present study, total nut intake was converted to g/d. Regarding the nut 
intake of the selected participants, 72 patients never consumed nuts (0 g/d) (non 
consumers (NC)), and 47 patients were regular consumers (RC), i.e. participants with an 
intake of ≥2.9 g/d of nuts in the preceding year (nut serving size, 28 g). The groups NC 
and RC were frequency matched group by sex, age and smoking status (Supporting 
Information Figure 1). In the present study, sporadic consumers (between >0g/d and < 
2.9 g/d of nut intake) were excluded to reduce “biological noise”.  
URINARY NUT METABOLOME ASSESSMENT  
At baseline, a single 24 h urine sample was collected from each participant. Urine 
samples were divided into aliquots, coded and stored at -80 ºC until analysis. Sample 
preparation was based on previously published methodology and was applied for the 
metabolomic analysis [13, 15]. Briefly, the samples were centrifuged for 5 min at 12000 
g. A 50 μL aliquot of the supernatant was mixed with an equal volume of Milli-Q water, 
and transferred into a 96-well plate for metabolomics analyses.  
Metabolomic analyses were conducted using an HPLC-Q-ToF-MS [Agilent 1200 Series 
Rapid Resolution HPLC system coupled to a hybrid quadrupole TOF (Q-ToF) QSTAR 





negative ion mode due to the chemical characteristics of the metabolites (observed 
before in our previous articles [13, 15]) and  following our previously published 
protocol [13]. A linear gradient elution was performed with a binary system consisting 
of [A] Milli-Q water 0.1% HCOOH (v/v) and [B] acetonitrile 0.1% HCOOH (v/v), at a 
constant flow rate of 600 μL min-1. The gradient elution (v/v) of [B] used was as 
follows (time, min; B, %): (0, 1), (4, 20), (6, 95), (7.5, 95), (8, 1), (12, 1). 
Data were extracted and aligned using MarkerView TM 1.2.1 (Applied Biosystems, 
MDS Sciex, Toronto, Ontario, Canada). The parameters used for the processing of raw 
data are listed in (Supporting Information Table 1. Before multivariate statistical 
analysis, mass feature data sets were log-transformed and Pareto-scaled using SIMCA-P 
+13.0 software (Umetrics, Umeå, Sweden). The mass features with coefficient of 
variation (CV) in urine samples greater than CV in pool of urine samples were removed 
to minimize the analytical variation. The mass features that were missing in at least 25% 
of samples from both groups were considered to be noise and they were excluded in the 
future analyses. 
The differences in the urine metabolome between the groups of study (NC versus RC) 
were explored using partial least-squares discriminant analysis with orthogonal signal 
correction (OSC-PLS-DA) (Supporting Information Figure 3 [16]. The quality of the 
models was evaluated through the goodness-of-fit parameter (R2X), the proportion of 
the variance of the response variable that is explained by the model (R2Y), and the 
predictive ability parameter (Q2). The validation of the models was evaluated with the 
permutation test (n=200) (20). As a final quality test, the whole data set was randomly 
split into four equal-size subsamples (25% of the sample each), three of which were 
used as the training set while the remaining one was used as the validation set. This 





once, and the correctly classified participants in each validation set (%) were calculated 
(Supporting Information Tables 2). Those mass features with the highest variable 
importance projection (VIP) values in the RC group (cut-off ≥ 2) were selected as the 
most relevant to explain the differences in urinary metabolomics profiles associated 
with nut intake. After that, a multistep procedure was used to annotate putative urinary 
markers of nut intake from the selected mass features [15]. Putatively annotated 
compounds were carried out by matching mass features with mass spectral databases 
(Human Metabolome Database [17], Metlin [18], MetFrag [19]) with a mass error 
tolerance of ±10 mDa (assigning a level 2 of the evidence in the identification in 
accordance with Metabolomics Standards Initiative criteria [20]). 
COGNITIVE FUNCTION ASSESSMENT 
Cognitive function was measured using the Mini-Mental State Examination (MMSE), 
which was administered at baseline and at 3-year follow-up. The MMSE is a validated 
method for assessing global cognitive function, and is widely used in both clinical 
practice and research [21, 22]. It evaluates five areas of cognitive functioning: 
orientation, registration, attention and calculation, recall, and language abilities. Overall 
scores range from 0 to 30, with high scores indicating better cognitive functioning 
(continuous variable).  
To calculate change in cognitive function, MMSE scores at baseline were subtracted 
from MMSE scores at 3-year follow-up. Thus, the subjects were divided into those with 
cognitive decline, defined as a decrease of two points or more from baseline assessment 
to 3-year follow-up [21, 23] and those without it (dichotomous variable). 
OTHER BASELINE COVARIATE ASSESSMENT 
Trained geriatricians conducted a comprehensive assessment of health, functional status 





energy (kcal/d) and alcohol (g/d) in the previous year were estimated using the FFQ 
[14] and an Italian food composition table [24]. Physical activity in the previous year 
was self-reported and was classified as [25]: 1) sedentary (completely inactive or light-
intensity physical activity, e.g. walking), 2) light (light-intensity physical activity for 2 
to 4 h/wk), and 3) moderate to intense (light-intensity physical activity of at least > 4 
h/wk or moderate-intensity physical activity of at least 1–2 h/wk). Smoking status 
(current, former or never-smoker), age, sex, BMI and education (years of schooling) 
were reported or calculated. Functional status was assessed using Katz’s Activities of 
Daily Living (ADL) [26], and the Lawton and Brody Instrumental Activities of Daily 
Living (IADL) [27] scales. Depressive symptoms were evaluated using the Center for 
Epidemiologic Studies Depression Scale (CES-D). A CES-D score of ≥16 was defined 
as a depressed mood [28]. Diseases were ascertained by combining information from 
self-reported physician diagnoses, pharmacological treatments, medical history, clinical 
examinations and blood tests. Diseases considered in this analysis were renal 
impairment, diabetes, cardiovascular diseases (myocardial infarction, angina pectoris 
and peripheral arterial disease), hypertension and stroke [29]. Inflammatory markers 
were measured in serum samples. Interleukin (IL)-6 and IL-1 receptor antagonist (IL-
1ra) were measured by high-sensitivity enzyme-linked immunoabsorbent assays 
(ELISAs) using commercial kits (BIOSOURCE International Inc., Camarillo, CA). The 
high-sensitivity C-reactive protein (hsCRP) was measured by an ELISA colorimetric 
competitive immunoassay that used purified protein and polyclonal anti-CRP 
antibodies. TNF-α was measured using multiplex technology (Human Serum Adipokine 






Descriptive analyses were performed to summarize information about the baseline 
characteristics of the study population. Differences between nut exposure groups, as 
well as differences between groups of cognitive function and differences between 
included and excluded participants groups, were tested by using a Student’s t-test, 
Mann-Whitney test or Chi-square test.  
Nut exposure was assessed using either dietary or urinary markers. To explore the 
relationships between dietary and urinary markers of nut intake, Spearman’s rank 
correlation coefficients were used. 
Multimetabolite prediction biomarker model of nut exposure 
To design multimetabolite biomarker panels associated with habitual dietary nut 
exposure, Tobit models [30], a class of censored regression model designed to mitigate 
the problem of zero-inflated data, were conducted to estimate β coefficients and their 
SEE with the identified urinary markers. The continuous variable on dietary marker of 
nut intake was used as dependent variable, where the threshold was a value of 0 g/d. 
Two full and two reduced multimetabolite biomarker panels related to nut intake were 
proposed using identified urinary metabolites.  The combination of individual 
biomarkers’ performance was evaluated using ROC curves. The likelihood ratio test 
was used for comparing the goodness of fit between the models. 
Associations between nut exposure and cognitive decline 
Associations between nut exposure, dietary and urinary markers (individuals and 
panels) and cognitive decline were analysed using two different but complementary 
statistical approaches: 1) associations with a change in cognitive function (continuous 
variable) over 3 years of follow-up, which were evaluated by estimating the 
standardized β coefficients and their 95% CI in linear regression models; and 2) 





follow-up, which were analysed by estimating the OR and its 95% CI in logistic 
regression models. Covariates in these statistical models were identified a priori as 
known risk factors or potential confounders. Four separate statistical models were 
performed: Model 1, adjusted for the baseline cognitive score (in order to correct for the 
“regression toward the mean”), for sex and age; Model 2, additionally adjusted for BMI, 
energy intake (except for urinary markers), alcohol consumption, education, physical 
activity and smoking status; and Model 3, additionally adjusted for depressive 
symptoms, stroke, cardiovascular diseases, hypertension and diabetes. Interactions with 
sex, age, BMI, education, smoking status and physical activity were evaluated between 
dietary nut marker and change in cognitive function by including product terms in the 
fully adjusted model. Moreover, the global performance of the associations between 
dietary and urinary markers of nut intake, adjusted for covariates (Model 3), and decline 
in cognitive function was evaluated using ROC curves and estimating the AUC (95% 
CI).  
All P values presented are two-tailed and were considered to be statistically significant 
when P<0.05. Data from metabolomic and epidemiologic analyses were analysed using 
R software version 3.2.4 (http://www.r-project.org) and the SPSS package program 
version 21.0 (SPSS, Chicago, IL). 
 
3. Results 
Descriptive study and dietary markers of nut exposure 
The baseline characteristics of the study population according to groups of dietary nut 
intake are presented in Table 1. There were 72 NC (0 g/d) and 47 RC (≥2.9 g/d). This 
study included 57 women and 62 men, with a mean age of 73 years. Participants in the 





(change) in cognitive function than those in the NC group. Of the 119 participants, 38 
had cognitive decline (Supporting Information Table 3).  
Urinary metabolomic markers assessment 
The results of the data acquisition quality and the quality of the models of metabolic 
profiling differentiation in the study are included in the Supporting Information 
Figure 2 and 3).  
A total of 18 urinary metabolites were identified or tentatively identified as 
discriminatory urinary metabolites related to dietary nut exposure including: 1) markers 
of the polyphenol microbial metabolism (urolithin A (glucuronide, sulphate and 
sluphoglucuronide), urolithin B (glucuronide), hydroxyhippuric acid, 
hydroxyphenylacetic acid); 2) a marker of the polyphenol intestinal metabolism 
(resveratrol-sulphate); 3) markers of the fatty acid metabolism (dodecanedioic and 
dimethylglutaric acids); 4) markers of the tryptophan metabolism (indole-3-acetic acid 
glucuronide and indoxyl sulphate / indoxylsulphuric acid); 5) a marker of the 
benzoxazinoid biosynthesis (dihydroxy-benzoxazinone) and 6) four unidentified 
markers (Table 2). According to the FFQ, there were statistically significant differences 
in wine consumption (P = 0.011) between the groups of dietary nut intake. Although 
among nuts, peanuts can also contain small amounts of resveratrol; it was assumed that 
resveratrol-sulphate is a biomarker of wine more than nut consumption [31]. Therefore, 
resveratrol-suphate metabolite was excluded from the subsequent analyses 
In order to improve the discrimination between the two groups (NC and RC), two full 
multimetabolite biomarker panels of nut intake were evaluated using Tobit models to 
estimate β coefficients and their SEE: Model A) all 13 known identified urinary 
metabolites; and Model B) a selection of 7 identified urinary metabolite biomarkers 





acid), which were previously associated with nut exposure as well (11, 12, 34). Two 
reduced biomarker panels were also evaluated: Model C) a reduced panel with the 4 
metabolite urinary biomarkers from Model A with the highest β coefficient (urolithin A 
glucuronide, hydroxyhippuric acid, hydroxyphenylacetic acid and dimethylglutaric 
acid); and Model D) a reduced panel with 2 metabolite biomarkers from Model B 
(urolithin A and its glucuronide) (Table 3). The reduced models were not statistically 
different from the full models in a likelihood ratio test (Models A and C: P =0.30; 
Models B and D: P = 0.35). Furthermore, the panels for Models A, B, C and D 
displayed 80.9, 74.5, 83.0 and 70.2 % sensitivity and 87.5, 69.4, 84.7 and 70.8 % 
specificity, with an AUC of 90.7, 76.7, 93.3 and 78.2 % (all P<0.001), respectively 
(Supporting Information Figure 4). 
Association between habitual nut exposure and cognitive function 
The associations between dietary and urinary (individual and combined) markers of nut 
intake and the change or the decline in the MMSE score at 3-year follow-up are 
reported in Table 4. In the fully adjusted linear regression models (Model 3), 
participants who reported a higher amount of nut intake in the FFQ (1 SD of difference) 
had better cognitive function (β: 0.25; 95% CI: 0.04, 0.46; P = 0.018). No statistically 
significant interactions were found between dietary nut intake and sex (P = 0.70), age 
(P = 0.66), BMI (P = 0.67), education (P = 0.47), smoking status (P = 0.40) and 
physical activity (P = 0.74) in relation to change in cognitive function (data not 
tabulated). Moreover, a statistically significant inverse association between nut intake 
and cognitive decline risk (OR: 0.78; 95% CI: 0.61, 0.99; P = 0.043) was observed.  
Regarding the urinary markers, participants who excreted a higher amount of urolithin 
A and its three conjugates (urolithin A glucuronide, urolithin A sulphate and urolithin A 





dimethylglutaric acid and dihydroxy--benzoxazinonealso had better cognitive function. 
Similar association between hydroxyphenylacetic acid and change in MMSE score was 
also observed, although the result was not statistically significant in the fully adjusted 
model. In addition, the four multimetabolite urinary biomarker panels of nut intake were 
inversely associated with the change in cognition. In the fully adjusted logistic 
regression models (Model 3), urolithin A, urolithin A sulphate, urolithin B, urolithin B 
glucuronide, hydroxyphenylacetic acid, dimethylglutaric acid and dihydroxy-
benzoxazinone levels were inversely associated with cognitive decline. No statistically 
significant associations between urolithin A glucuronide, urolithin A sulphoglucuronide 
and dodecanedioic acid levels and cognitive decline were observed. In the fully adjusted 
model, multimetabolite urinary biomarker panels of nut intake (Models A, B and C), 
except for Model D, were also associated with cognitive decline (Table 4). 
The ROC curves and the corresponding AUC (95% CI), as well as the calculation of the 
sensitivity and specificity of dietary and urinary (individual and combined) markers of 
nut intake for the prediction of cognitive decline adjusted for all the potential factors, 
are shown in Figure 1 and (Supporting Information Table 4). The AUC for the 
dietary marker and multimetabolite urinary biomarker models (Models A, B, C and D) 
was 73.2, 74.8, 72.8, 73.1 and 71.3, respectively, and all were statistically significant (P 
< 0.001). All sensitivity and specificity values from these models were higher than 60 
and 70 %, respectively (Supporting Information Table 4).  
 
4. Discussion  
Our prospective study in non-demented older subjects shows that high intake of nuts 
was associated with better cognitive function and a lower risk of cognitive decline over 





untargeted metabolomics data to investigate the association between nut intake and 
cognitive decline risk. In addition, our results support that the use of multiple nut 
biomarkers in epidemiological studies may provide a more accurate assessment of the 
nut exposure than the use of individual biomarkers and therefore a proper estimation of 
the associations with health outcomes. 
We found an association between high intake of nuts and lower cognitive decline risk 
whether the nuts exposure is measured based on the traditional FFQ or using a 
multimetabolite biomarker model. In line with previous prospective studies, nuts 
consumption was associated with a better cognitive function [32] and with a lower 
global cognitive decline [33]. Evidence focused on nut exposure alone is limited, but 
several studies have been conducted on dietary patterns including nuts as a key 
component. The Mediterranean diet supplemented with nuts was associated with 
improved cognitive function [34]. In a previous InCHIANTI study, a polyphenol-rich 
diet intake was related to a lower cognitive decline [35]. The mechanism by which nut 
intake protects cognitive function during aging is not clearly defined. Oxidative stress, 
inflammation and reduced cerebral blood flow have been considered to be important 
mechanisms leading to cognitive decline in older subjects [36]. Thus, nuts, alone or as 
part of healthy dietary patterns, may exert beneficial effects against the development of 
cognitive decline due to their high concentrations of antioxidants [37], including 
polyphenols (e.g. proanthocyanidins in almonds and hazelnuts; ellagitannins in walnuts 
and hazelnuts), MUFA (e.g. oleic acid in almonds and hazelnuts) [38], PUFA (e.g. α-
linolenic and linoleic acid in walnuts) and vitamins [10]. 
Taking into consideration the whole composition of nuts, a multibiomarker approach to 
assess overall consumption may be more accurate for predicting nut exposure than the 





In the present study, urinary multimetabolite biomarker models of nut exposure (mainly 
Model C composed by Urolithin A glucuronide, hydroxyhippuric acid, 
hydroxyphenylacetic acid and dimethylglutaric acid) presented a greater predictive 
ability as a biomarker of nut intake, than individual markers. The discriminative 
capacity of Model C, as well as of urolithin A glucuronide, to classify subjects 
according to cognitive decline was observed. These may be valuable dietary biomarkers 
of cognitive decline, because of the potential role of polyphenols and polyunsaturated 
fatty acids in reducing oxidative stress and inflammation [10]. However, no statistically 
significant differences across nut groups in relation to inflammatory markers were 
observed (data not tabulated).  
Urolithin A was the most discriminant phenolic marker also observed elsewhere [15, 
39, 40]. Urolithins are gut microbiota products from ellagic acid and ellagitannins. In 
the lower gastrointestinal tract, these compounds are converted into urolithins, which 
are absorbed and metabolized to finally circulate in blood reaching different tissues 
prior to excretion [41]. Hence, these results represent an important step ahead in the 
validation of these compounds as biomarkers of nut exposure. Recently, three urolithin 
phenotypes were observed [42]. A higher percentage of “phenotype B”, which produced 
isourolithin A and/or urolithin B in addition to urolithin A, was observed in those 
participants with chronic disease associated with microbial imbalance. In this study, the 
prevalence of “Phenotype A” (only urolithin A conjugates excreted), “Phenotype B” 
and “Phenotype 0” (no detected urolithins) with cognitive decline was 20, 20 and 60 %, 
respectively (P = 0.78). This may be due to the low sample size (n = 47, loss due to 
phenotypic variation) (data not tabulated). Therefore, further studies are needed to 
evaluate whether this phenotypic variation could be a biomarker associated with 





The presence of other microbial-derived metabolites including flavan-3-ols (2-
hydroxyphenylacetic acid) and procyanidins (hydroxyhippuric acid), from walnuts [13, 
39, 43, 44] and almonds [45], respectively and markers of the tryptophan metabolism 
such as indole-3-acetic-acid-O-glucuronide and indoxyl sulphate/indoxylsulphuric acid, 
mainly from the consume of walnuts [46] highlight again an interplay between nut 
intake, gut microbiota and cognitive decline. Currently, the brain-gut-microbiome 
connection is a hot research topic. Nuts, which are rich in fibre, omega-3 fatty acids and 
polyphenols, increase healthy gut microbiota and may improve cognition [47–49]. For 
example, the excretion of urinary indoles reflects a variation in gut microbiota 
composition in relation to their role in inhibition or promotion of the growth of specific 
bacterial species, also observed in a number of diseases states [46].   
Generally, evidence concerning nut exposure and cognition relies on the measurement 
of nut exposure using mainly self-reported dietary questionnaires. Consequently, studies 
using biomarkers of nut exposure are needed to confirm these potential protective 
effects. Therefore, the use of a metabolomic approach to identify and validate proper 
and predictive nutritional biomarkers is now highly promising [11]. 
The main strengths of this study were its longitudinal design and the assessment of 
habitual nut exposure with the use of a nut-derived metabolites panel as a nutritional 
biomarker. The combination of different metabolites as a nutritional biomarker provided 
a more accurate estimation than that provided by only a single biomarker [15]. Another 
strength was the use of a validated method assessment test to evaluate cognitive decline 
[21, 22]. Finally, our models were adjusted for the most important confounding 
variables related to nut exposure and cognitive decline; however, possible residual 





Nevertheless, this study had some limitations. First, it is important to bear in mind that 
no type specification of nut consumption was discerned in the administered FFQ, 
although the percentage consumption of individual tree nuts and peanuts consumed as a 
whole in Italy (EPIC study) was approximately 60 (where walnuts are more consumed 
than almonds and hazelnuts) and 32 %, respectively [50]. In addition, the mean ± SD 
intake of nuts in their study (n = 3961; 1.7 ± 0.2 g/d) was similar to that in our study (n 
= 119; 1.9 ± 3.2 g/d). However, the present study sample might not be representative of 
nut consumption in general Italian population, because InCHIANTI was performed in 
community-dwelling older subjects living in two sites in Tuscany (Italy). Second, the 
present study population was aged ≥ 65 and therefore may be less accurate in recalling 
food intake, although demented participants were excluded. Finally, because biomarker 
assessment was performed only once at baseline, it may not necessarily reflect the 
participants’ long-term nut consumption. Although this is to be expected with aging 
[51], there was a decrease in the nut intake during the follow-up, which was 1.9 and 0.9 
g/d at baseline and at the 3-year follow-up visit, respectively (data not tabulated). Their 
r was 0.46 (P < 0.001).  
In conclusion, this study showed that a higher habitual exposure to nuts was associated 
with a lower risk of cognitive decline in a cohort of older individuals. Moreover, this 
study opens up a large area of research with more reliable and accurate tools for 
identifying and validating new biomarkers of nut exposure and evaluating their 
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Table 1. Baseline characteristics of the study population according to groups of habitual dietary nut intake1 
 
 Total Non-consumers  Regular Consumers P 
Participants, n (%) 119 72 (60.5) 47 (39.5) ‒ 
Nut, g/d 1.9 ± 3.22 0.0 ± 0.0 4.9 ± 3.3 <0.001 
Energy, kcal/d 2014 ± 589 1804 ± 541 2337 ± 511 <0.001 
Alcohol, g/d 17.3 ± 22.9 14.0 ± 18.7 22.3 ± 27.7 0.054 
Demographics     
Sex, F, n (%) 57 (47.9) 36 (50.0) 21 (44.7) 0.57 
Age, y 73.0 ± 5.9 73.5 ± 6.2 72.2 ± 5.2 0.23 
BMI, kg/m² 27.5 ± 3.8 27.1 ± 3.7 27.9 ± 3.8 0.27 
Physical Activity, n (%)    0.53 
       Sedentary 18 (15.1) 9 (12.5) 9 (19.1)  
       Light 55 (46.2) 33 (45.8) 22 (46.8)  





Smoking status, n (%)    0.18 
       Never 51 (42.9) 26 (36.1) 25 (53.2)  
       Current 35 (29.4) 24 (33.3) 11 (23.4)  
       Former 33 (27.7) 22 (30.6) 11 (23.4)  
Education (years of school) 6.0 ± 3.5 5.9 ± 3.7 6.1 ± 4.2 0.84 
Disability in ≥1 ADL, n (%) 6 (5.0) 6 (8.3) 0 (0.0) 0.042 
Disability in ≥1 IADL, n (%) 14 (11.8) 8 (11.1) 6 (12.8) 0.78 
Inflammatory markers     
IL-6, pg/mL 2.8 (1.9‒3.9)3 2.4 (1.8‒3.8) 3.0 (2.2‒4.9) 0.11 
TNF-α, pg/mL 4.4 (2.9‒5.6) 4.2 (2.8‒5.4) 4.8 (3.6‒5.9) 0.30 
hsCRP, µg/mL 2.7 (1.5‒4.8) 2.5 (1.4‒5.0) 3.0 (1.5‒4.8) 0.36 
IL-1ra, pg/mL 121.3 (93.4‒187.1) 120.0 (84.7‒193.9) 125.8 (93.8‒178.5) 0.99 
Diseases and conditions     
Renal impairment, n (%) 67 (57.8) 43 (61.4) 24 (52.2) 0.32 





Cardiovascular disease, n (%) 26 (21.8) 12 (16.7) 14 (29.8) 0.09 
Hypertension, n (%) 62 (52.1) 38 (52.8) 24 (51.1) 0.86 
Stroke, n (%) 11 (9.2) 7 (9.7) 4 (8.5) 0.82 
Depressive symptoms, CES-D score ≥16, n (%) 33 (27.7) 19 (26.4) 14 (29.8) 0.69 
Cognitive function     
Subjects with cognitive decline, n (%) 38 (31.9) 28 (38.0) 10 (21.0) 0.04 
Baseline global cognitive function, MMSE score 25.7 ± 2.5 24.6 ± 4.4 25.7 ± 2.7 0.87 
Global cognitive function change -0.5 ± 3.4 -1.1 ± 3.7 0.4 ± 2.6 0.012 
1Descriptive analyses were compared between groups of nut exposure with the use of a Student’s t-test, Mann-Whitney test or Chi-square test as appropriate. No missing 
participants. ADL, Activities of Daily Living; CES-D, Center for Epidemiologic Studies Depression scale; hsCRP, high-sensitivity C-Reactive Protein; IADL, Instrumental 
Activities of Daily Living; IL-1ra, Interleukin-1 receptor antagonist; IL-6, Interleukin-6; MMSE, Mini-Mental State Examination; TNF-α, Tumors Necrosis Factor-α. 
2Mean ± SD (all such values). 
















Assignation Potential biomarker VIP 
Markers of the polyphenol microbial metabolism  
1 6.45 227.0327 227.0350 2.3 [M – H]- Urolithin A 3.75 
    228.0365 228.0384 1.9 13C[M – H]-   2.56 
2 5.38 403.0626 403.0671 4.5 [M – H]- Urolithin A glucuronide 4.78 
    404.0663 404.0705 4.1 13C[M – H]-   4.38 
    227.0329 227.0350 2.1 [M – H – glucuronide]-   3.43 
3 6.64 306.9884 306.9918 3.4 [M – H]- Urolithin A sulphate 3.96 
4 5.23 483.0187 483.0239 5.2 [M – H]- Urolithin A sulphoglucuronide 3.01 
5 6.80 211.0387 211.0401 1.4 [M – H]- Urolithin B 2.00 
6 6.30 387.0650 387.0721 7.1 [M – H]- Urolithin B glucuronide 2.44 
  - 388.0708 388.0755 4.7 13C[M – H]-   2.23 
- - 211.0386 211.0401 1,5 [M – H – glucuronide]- - - 
7 5.00 151.0579 151.0594 1.5 13C[M – H – COO]- Hydroxyhippuric acid 2.66 
- - 150.0529 150.0560 3,1 [M – H – COO]- - - 
- 4.98 194.0367 194.0459 9,2 [M – H]- - - 
8 4.50 151.0383 151.0401 1.8 [M – H]- 2-Hydroxyphenylacetic acid 3.59 
Markers of the polyphenol intestinal metabolism 
9 6.95 307.0265 307.0282 1.7 [M – H]- Resveratrol-sulphate 2.99 





    227.0702 227.0714 1.2 [M – H – sulphate]-   2.72 
- - 228.0732 228.0748 1.6 13C[M – H – sulphate]- - - 
Markers of the fatty acid metabolism 
10 6.77 229.1429 229.1445 1.6 [M – H]- Dodecanedioic acid 2.15 
    230.1468 230.1479 1.1 13C[M – H]-   2.06 
11 4.07 160.0700 160.0697 0.3 13C[M – H]- Dimethylglutaric acid 2.70 
- - 159.0664 159.0663 0.1 [M – H]- - - 
    115.0769 115.0764 0.5 [M – H – COO]-   2.09 
- - 97.0657 97.0659 0.2 [M – H – COO – H2O]- - - 
Markers of the tryptophan metabolism 
12 5.28 175.0265 175.0594 0.3 13C[M – H – glucuronide]- Indole-3-acetic acid glucuronide 2.08 
- - 174.0569 174.0560 0.9 [M – H – glucuronide]- - - 
- - 351.0911 351.0915 0.4 13C[M – H]- - - 
- - 350.0878 350.0881 0.3 [M – H]- - - 
13 4.55 212.0018 212.0023 0.5 [M – H]- Indoxyl sulphate / Indoxylsulphuric acid 2.58 
    213.0048 213.0057 0.9 13C[M – H]-   2.05 
    132.0448 132.0455 0.7 [M – H – sulphate]-   2.13 
- - 425.0117 425.0119 0.2 [2M– H]- - - 
Markers of the benzoxazinoid biosynthesis 
14 4.93 180.0373 180.0302 7.1 [M – H]- Dihydroxy-benzoxazinone 3.14 
Unidentified markers 





    310.0437     13C[M – H]-   2.27 
    311.0381     213C[M – H]-   2.48 
16 6.15 359.1329     [M – H]- Unknown B (glucuronide derivative) 2.04 
- - 183.1024 - - [M – H – glucuronide]- - - 
17 6.54 397.1102     [M – H]- Unknown C 2.66 
- - 398.1141 398,1136 0,5 13C[M – H]- - - 
18 6.22 373.1150     [M – H]- Unknown D 2.25 
    374.1126     13C[M – H]-   2.34 
1One-class OSC-PLS-DA model (NC versus RC) was used. NC, non-nut consumers; RT, retention time; VIP, variable importance projection; RC, regular nut consumers. 






Table 3. Multimetabolite prediction biomarker models associated with habitual nut intakea 
Model 
Dietary nut exposure urinary 
biomarker 
β ± SEE P Model Dietary nut exposure biomarker β ± SEE P 
A Urolithin A -0.033 ± 1.196 0.98 C Urolithin A glucuronide 2.905 ± 0.676 <0.001 
 Urolithin A glucuronide 2.193 ± 1.032 0.034  Hydroxyhippuric acid 3.436 ± 0.894 <0.001 
 Urolithin A sulphate 0.088 ± 1.332 0.95  Hydroxyphenylacetic acid 3.263 ± 0.763 <0.001 
 Urolithin A sulphoglucuronide 0.011 ± 1.242 0.99  Dimethylglutaric acid 3.452 ± 1.124 <0.001 
 Urolithin B 0.240 ± 1.392 0.86     
 Urolithin B glucuronide 0.670 ± 1.212 0.58     
 Hydroxyhippuric acid 3.453± 0.971 <0.001     
 Hydroxyphenylacetic acid 2.887 ± 0.795 <0.001     
 Dodecanedioic acid 1.102 ± 0.850 0.19     
 Dimethylglutaric acid 2.339 ± 1.220 0.055     
 Indole-3-acetic-acid-O-glucuronide 1.834± 0.965 0.057     






 Dihydroxy-benzoxazinone -0.186 ± 0.881 0.83     
B Urolithin A 1.380 ± 1.319 0.29 D Urolithin A 1.899 ± 0.914 0.038 
 Urolithin A glucuronide 3.023 ± 1.191 0.011  Urolithin A glucuronide 2.578 ± 0.921 0.005 
 Urolithin A sulphate 1.811 ± 1.381 0.19     
 Urolithin A sulphoglucuronide -2.163 ± 1.423 0.13     
 Urolithin B -0.917 ± 1.570 0.56     
 Urolithin B glucuronide 0.791 ± 1.368 0.56     
 Dodecanedioic acid 1.245 ± 0.895 0.16     





Table 4. Associations between nut exposure and cognitive declinea 
 
Nut exposure 
Change in cognitive function Decline in cognitive function 
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aLinear and logistic regression models were used, and the following three separate models are presented: model 1, which was adjusted for baseline score of cognitive function, 
sex and age; model 2, which was further adjusted for BMI, energy intake (only diet), alcohol consumption, education, physical activity and smoking status; and model 3, 
which was further adjusted for depressive symptoms, stroke, cardiovascular disease, hypertension and diabetes. 
b Multimetabolite urinary biomarkers models evaluated using Tobit models as follows: Model A) all 13 known identified urinary metabolite; Model B) a selection of 7 
identified urinary metabolite biomarkers (urolithin A and its three conjugates, urolithin B and its glucuronide, and dodecanedioic acid; Model C) a reduced panel with 4 
metabolite biomarkers from Model A (urolithin A glucuronide, hydroxyhippuric acid, hydroxyphenylacetic acid and dimethylglutaric acid); and Model D) a reduced panel 
with 2 metabolite biomarkers from Model B (urolithin A and its glucuronide).
 
 
 
 
 
